Literature DB >> 6467689

Objective monitoring of activity in Wegener's granulomatosis by measurement of serum C-reactive protein concentration.

C R Hind, C G Winearls, C M Lockwood, A J Rees, M B Pepys.   

Abstract

Serial measurements of the serum concentration of C-reactive protein were made in 38 patients with Wegener's granulomatosis during a period of 6 years. The concentration was always elevated when the disease was active, even in patients receiving immunosuppressive treatment, and fell rapidly in association with clinical remission induced by immunosuppression. During periods of complete remission, in the absence of any intercurrent condition, the value remained within the normal range. The correlation between C-reactive protein level and disease activity was much closer than that between erythrocyte sedimentation rate and disease activity. These results indicate that serial measurement of the serum C-reactive protein fills the urgent need for an objective index of the activity of Wegener's granulomatosis and its response to therapy.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6467689

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  16 in total

1.  Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Paul A Monach; Gunnar Tomasson; Ulrich Specks; John H Stone; David Cuthbertson; Jeffrey Krischer; Linna Ding; Fernando C Fervenza; Barri J Fessler; Gary S Hoffman; David Ikle; Cees G M Kallenberg; Carol A Langford; Mark Mueller; Philip Seo; E William St Clair; Robert Spiera; Nadia Tchao; Steven R Ytterberg; Yi-Zhong Gu; Ronald D Snyder; Peter A Merkel
Journal:  Arthritis Rheum       Date:  2011-12

Review 2.  Clinical immunology.

Authors:  R J Powell
Journal:  Postgrad Med J       Date:  1991-11       Impact factor: 2.401

3.  Vascular damage in Wegener's granulomatosis and microscopic polyarteritis: presence of anti-endothelial cell antibodies and their relation to anti-neutrophil cytoplasm antibodies.

Authors:  C O Savage; B E Pottinger; G Gaskin; C M Lockwood; C D Pusey; J D Pearson
Journal:  Clin Exp Immunol       Date:  1991-07       Impact factor: 4.330

Review 4.  Assessment of disease activity in systemic vasculitis.

Authors:  W Y Tse; P Cockwell; C O Savage
Journal:  Postgrad Med J       Date:  1998-01       Impact factor: 2.401

5.  Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis.

Authors:  Paul A Monach; Roscoe L Warner; Gunnar Tomasson; Ulrich Specks; John H Stone; Linna Ding; Fernando C Fervenza; Barri J Fessler; Gary S Hoffman; David Iklé; Cees G M Kallenberg; Jeffrey Krischer; Carol A Langford; Mark Mueller; Philip Seo; E William St Clair; Robert Spiera; Nadia Tchao; Steven R Ytterberg; Kent J Johnson; Peter A Merkel
Journal:  Ann Rheum Dis       Date:  2012-09-12       Impact factor: 19.103

6.  Autoantibodies against cytoplasmic structures of neutrophil granulocytes in Wegener's granulomatosis.

Authors:  G Lüdemann; W L Gross
Journal:  Clin Exp Immunol       Date:  1987-08       Impact factor: 4.330

7.  Serum markers of T cell activation in relapses of Wegener's granulomatosis.

Authors:  C A Stegeman; J W Tervaert; M G Huitema; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1993-03       Impact factor: 4.330

8.  Cardiac involvement in Wegener's granulomatosis.

Authors:  N E Goodfield; S Bhandari; W D Plant; A Morley-Davies; G R Sutherland
Journal:  Br Heart J       Date:  1995-02

9.  Serum C-reactive protein concentration in the management of infection in patients treated by continuous ambulatory peritoneal dialysis.

Authors:  C R Hind; S P Thomson; C G Winearls; M B Pepys
Journal:  J Clin Pathol       Date:  1985-04       Impact factor: 3.411

10.  Titration of antibodies against neutrophil cytoplasmic antigens is useful in monitoring disease activity in systemic vasculitides.

Authors:  W Egner; H M Chapel
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.